British Journal of Haematology · 2020 · 36 citations · 24 references
MedicineOncologyPharmacologyChemotherapyMolecular OncologyOncogenesLymphoid NeoplasmsLymphoid TumorsNatural Killer T-cell LymphomaNatural Killer-cell LymphomaPhosphatidylinositol 3-Kinase PathwayPi3 Kinase-akt SignalingPi3k InhibitorsPi3k SignalingPi3k-akt Signaling PathwayPten Signaling
Summary Peripheral T‐cell lymphomas (PTCL) and natural killer (NK)/T‐cell lymphomas (NKTCL) are a heterogeneous group of aggressive malignancies with dismal outcomes and limited treatment options. While the phosphatidylinositol 3‐kinase (PIK3) pathway has been shown to be highly activated in many B‐cell lymphomas, its therapeutic relevance in PTCL and NKTCL remains unclear. The aim of this study is to investigate the expression of PIK3 and phosphatase and tensin homolog (PTEN) in these subtypes of lymphoma and to identify potential therapeutic targets for clinical testing. Therefore, the expression of PIK3α, PIK3β, PIK3γ, PIK3δ and PTEN was analyzed in 88 cases of PTCL and NKTCL samples by immunohistochemistry. All PTCL and NKTCL samples demonstrated high expression of PIK3 isoforms. In particular, high PIK3α expression was significantly associated with poor survival, even after adjustment for age, International Prognostic Index (IPI) score and anthracycline‐based chemotherapy in first line. Notably, copanlisib, a pan‐class I inhibitor with predominant activities towards PIK3α and PIK3δ isoforms, effectively inhibited phosphorylation of AKT, 4E‐BP‐1 and STAT3, causing G 0 /G 1 cell cycle arrest and resulting in suppression of tumour cell growth in vitro and in vivo . This study provides evidence that targeting the PIK3 pathway, particularly simultaneous inhibition of PIK3α and δ, could be a promising approach for the treatment of PTCL and NKTCL.
24
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal, Brad S. Kahl, Sven de Vos et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Impaired B and T Cell Antigen Receptor Signaling in p110δ PI 3-Kinase Mutant Mice
Klaus Okkenhaug, Antonio Bilancio, Géraldine Farjot et al. · Science · 2002 · 937 citations
Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer
Khaled Ali, Dalya R. Soond, Roberto Piñeiro et al. · Nature · 2014 · 543 citations · Full text
Life Sciences, Immunology, Oncology +10
Essential role for the p110δ phosphoinositide 3-kinase in the allergic response
Khaled Ali, Antonio Bilancio, Matthew J. Thomas et al. · Nature · 2004 · 379 citations